Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
Saved in:
| Title: | Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells. |
|---|---|
| Authors: | Navas T; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America., Pfister TD; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America., Colantonio S; Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America., Aziz A; Biosciences Division, Argonne National Laboratory, Argonne, Illinois, United States of America., Dieckman L; Biosciences Division, Argonne National Laboratory, Argonne, Illinois, United States of America., Saul RG; Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America., Kaczmarczyk J; Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America., Borgel S; Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, Maryland, United States of America., Alcoser SY; Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, Maryland, United States of America., Hollingshead MG; Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, Maryland, United States of America., Lee YH; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America., Bottaro DP; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America., Hiltke T; Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiatives, National Cancer Institute, Bethesda, Maryland, United States of America., Whiteley G; Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America., Takebe N; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America., Kinders RJ; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America., Parchment RE; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America., Tomaszewski JE; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America.; Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America. |
| Source: | PloS one [PLoS One] 2018 Jun 21; Vol. 13 (6), pp. e0199361. Date of Electronic Publication: 2018 Jun 21 (Print Publication: 2018). |
| Publication Type: | Journal Article; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 29928062 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Navas+T%22">Navas T</searchLink>; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Pfister+TD%22">Pfister TD</searchLink>; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Colantonio+S%22">Colantonio S</searchLink>; Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Aziz+A%22">Aziz A</searchLink>; Biosciences Division, Argonne National Laboratory, Argonne, Illinois, United States of America.<br /><searchLink fieldCode="AU" term="%22Dieckman+L%22">Dieckman L</searchLink>; Biosciences Division, Argonne National Laboratory, Argonne, Illinois, United States of America.<br /><searchLink fieldCode="AU" term="%22Saul+RG%22">Saul RG</searchLink>; Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Kaczmarczyk+J%22">Kaczmarczyk J</searchLink>; Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Borgel+S%22">Borgel S</searchLink>; Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Alcoser+SY%22">Alcoser SY</searchLink>; Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Hollingshead+MG%22">Hollingshead MG</searchLink>; Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Lee+YH%22">Lee YH</searchLink>; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Bottaro+DP%22">Bottaro DP</searchLink>; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Hiltke+T%22">Hiltke T</searchLink>; Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiatives, National Cancer Institute, Bethesda, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Whiteley+G%22">Whiteley G</searchLink>; Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Takebe+N%22">Takebe N</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Kinders+RJ%22">Kinders RJ</searchLink>; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Parchment+RE%22">Parchment RE</searchLink>; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Tomaszewski+JE%22">Tomaszewski JE</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Doroshow+JH%22">Doroshow JH</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America.; Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101285081%22">PloS one</searchLink> [PLoS One] 2018 Jun 21; Vol. 13 (6), pp. e0199361. <i>Date of Electronic Publication: </i>2018 Jun 21 (<i>Print Publication: </i>2018). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Public+Library+of+Science%22">Public Library of Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101285081 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1932-6203 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2219326203%22">19326203 </searchLink><i>NLM ISO Abbreviation: </i>PLoS One <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=29928062 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1371/journal.pone.0199361 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e0199361 Titles: – TitleFull: Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Navas T – PersonEntity: Name: NameFull: Pfister TD – PersonEntity: Name: NameFull: Colantonio S – PersonEntity: Name: NameFull: Aziz A – PersonEntity: Name: NameFull: Dieckman L – PersonEntity: Name: NameFull: Saul RG – PersonEntity: Name: NameFull: Kaczmarczyk J – PersonEntity: Name: NameFull: Borgel S – PersonEntity: Name: NameFull: Alcoser SY – PersonEntity: Name: NameFull: Hollingshead MG – PersonEntity: Name: NameFull: Lee YH – PersonEntity: Name: NameFull: Bottaro DP – PersonEntity: Name: NameFull: Hiltke T – PersonEntity: Name: NameFull: Whiteley G – PersonEntity: Name: NameFull: Takebe N – PersonEntity: Name: NameFull: Kinders RJ – PersonEntity: Name: NameFull: Parchment RE – PersonEntity: Name: NameFull: Tomaszewski JE – PersonEntity: Name: NameFull: Doroshow JH IsPartOfRelationships: – BibEntity: Dates: – D: 21 M: 06 Text: 2018 Jun 21 Type: published Y: 2018 Identifiers: – Type: issn-electronic Value: 1932-6203 Numbering: – Type: volume Value: 13 – Type: issue Value: 6 Titles: – TitleFull: PloS one Type: main |
| ResultId | 1 |
